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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Explaining the risks and benefits of recombinant tissue-plasminogen
activator (rtPA) to eligible patients with acute ischemic stroke (AIS) within a few minutes is
important but difficult. We examined whether a new thrombolysis program can decrease the
door-to-needle (DTN) time when treating patients with AIS.
Methods: A new rtPA thrombolysis program with video assistance was adapted for patients with
AIS and their families.We retrospectively compared outcome quality before (2009e2011) and af-
ter (2012) the programbegan. Outcomes included DTN time, the percentage of rtPA thrombolysis
within 3 hours of onset in all hospitalized patients with AIS who presented within 2 hours of onset
(2hr%) and the percentage of rtPA thrombolysis in all hospitalized patients with AIS (AIS%).
Results: We recruited patients with AIS who had undergone thrombolytic therapy before
(nZ 18) and after (nZ 14) the initiation of the new program. DTN time decreased (93  24 mi-
nutes to 57 14 minutes, p< 0.001) and the AIS% increased (2% to 5%, pZ 0.010) after the pro-
gram. The 2hr% marginally significantly increased (18% to 33%, pZ 0.080).rs declared no conflict of interest.
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decreased DTN time and increased the treatment rate of patients with AIS.
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Recombinant tissue-type plasminogen activator (rtPA) is
the only approved effective thrombolytic agent for acute
ischemic stroke (AIS). When administered intravenously
within 3 hours of symptom onset, rtPA increases by at least
33% the chance of functional independence within 3
months, but also increases by at least 1000% the risk of
intracerebral hemorrhage (ICH) for patients with AIS.1 The
narrow window of treatment time and the potential risk of
ICH when using rtPA has substantially limited the use of this
treatment.2 The Taiwan Stroke Registry shows that from
2006 through 2008, only approximately 1.5% of all hospi-
talized patients with AIS and 8.8% of those who presented
within 2 hours of symptom onset were given intravenous
(IV) rtPA.3 In Taiwan and other countries, informed consent
must be obtained before thrombolytic therapy is instituted.
Because stroke is an acute and serious neurologic disorder,
it may be difficult for physicians to explain the risks and
benefits of rtPA to patients or their surrogates in an
emergency. Visual analogues such as figures and outcome
wheels have been used to convey such important informa-
tion about rtPA to those for whom it is potentially war-
ranted.4,5 However, the effect of these methods of
communication has been insufficiently studied, especially
in community hospitals. In the current study, we compared
the effect of a thrombolysis program with video-assisted
therapeutic risk communication on the improvement of
the quality of care for patients with AIS.
Patients and methods
Hospital setting
The Tainan Sin Lau hospital (SLH; Tainan, Taiwan) is a
community regional teaching hospital and a secondary
referral center in the East District of Tainan City. SLH has
285 acute beds, with an average of 273 hospitalized pa-
tients per day in 2012. Three board-certified neurologists
see approximately 300 patients with AIS per year.
Thrombolytic program
SLH set up its own primary stroke center in 2009 and pro-
vided thrombolytic therapy 24 hours a day, 7 days a week for
indicated patients with AIS who presented within 3 hours of
symptom onset. The Taiwan Department of Health
accredited the SLH Stroke Center to perform stroke throm-
bolysis in 2011. We followed the treatment guidelines of the
Taiwan Stroke Society6 when selecting patients eligible for
rtPA. If eligible, patients with AIS are treated with an IV
dosage of 0.9 mg rtPA/kg of body weight.7 The initial 10% of
the rtPAwas administered with an IV bolus injection within 1
minute, whereas the other 90% was administered via IV dripfor 1 hour.7 Because treatment initiation time was critical
and limited, we accepted from the patient or the patient’s
surrogate an oral statement of the patient’s body weight to
calculate the required dose of rtPA.
From 2012, several new strategies have been imple-
mented to reduce DTN time. For example, the computed
tomography (CT) room has been moved from the first
basement level to the first floor to reduce the delay in
diagnostic imaging. In addition, a special plastic bag is now
used when transferring blood samples to indicate that the
blood tests should be done as soon as possible. A new
thrombolysis program with video-assisted therapeutic risk
communication has also been initiated. Briefly, all patients
with hyperacute stroke who are potentially eligible for rtPA
and their family are shown a 5-minute animated video. The
content of the video is now available online (www.stroke.
org.tw). It simply illustrates the pathophysiology of AIS,
the mechanism of rtPA to dissolve the thrombus, and the
overall risks and benefits of the treatment. This video is
usually shown while the patient is waiting for an emergency
brain CT or an evaluation by the neurologist on duty. After
they have watched the video, the patient and family
members can direct questions about the procedure to the
emergency physician or neurologist on duty. After obtaining
an evaluation of the patient and the informed consent of
the patient or surrogate, the neurologist on duty makes the
final decision on patient eligibility for rtPA treatment.
Study design
This retrospective study used preexisting stroke registry
materials. SLH started to register patients hospitalized with
AIS in 2009 based on the format of the Taiwan Stroke Registry
(TSR). To assess the video-assisted thrombolytic program’s
effectiveness, all patients with AIS who underwent intrave-
nous rtPA in SLH were separated into two groups: before
(2009e2011) and after (2012) the program’s implementation.
Baseline demographics, comorbidities, current medications
before treatment, pretreatment National Institute of Health
Stroke Scale (NIHSS) total score, actual dose of rtPA (mg/kg of
body weight), as well as the treatment outcomes of patients
in the two groups, were all retrieved from the stroke registry
data. The TSR protocol was approved by the SLH institutional
review board before the current study began.
Outcome measures
The main outcome of interest in the current study was DTN
time; specifically, the time spent from thepatient’s arrival to
IV bolus injection of rtPA. Other structural outcomes were
also selected for comparison: the percentage of DTN
time  60 minutes, door-to-CT time, onset-to-needle time,
door-to-laboratory time, the percentage of rtPA thrombol-
ysis within 3 hours of onset in all hospitalized patients with
AIS who presented within 2 hours of onset (2hr%), and the
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with AIS (AIS%). A modified Rankin scale8 (mRS)  2 upon
discharge was considered the effectiveness outcome,
whereas symptomatic ICH (sICH) after rtPA was considered
the safety outcome. The presence of sICH is defined
following the National Institute of Neurological Diseases and
Stroke (NINDS) definition1: ICH with deterioration of any
neurological symptoms (NIHSS score  1) or death.
Statistical analyses
Continuous variables are presented as means  standard
deviation, ordinal or ranked data (e.g., NIHSS) are pre-
sented as medians (interquartile range), and categorical
data are presented as percentages. To examine the dif-
ferences in variables between the two groups, two sample t
tests were used for continuous variables, and the Pearson
c2 test or Fisher exact test was used for dichotomous var-
iables when indicated. Significance was set at p < 0.05
(two-tailed). Odds ratios (ORs) with 95% confidence in-
tervals (CIs) were used to measure the amplitude of in-
crease in chance before and after the intervention. SAS
version 9.2 for Windows (SAS Institute, Cary, NC, USA) was
used for all statistical analyses.
Results
We recruited 32 consecutive patients with AIS who had
been underwent thrombolytic therapy: 18 patients beforeTable 1 Baseline characteristics of patients with acute ischem
plasminogen activator treatment before and after the implemen
Characteristics Befo
Demographics
Age (y) 64 
Male 67
Smoking 22
SBP (mmHg) 164
DBP (mmHg) 95 
Comorbidities
Hypertension 89
Diabetes 28
Hyperlipidemia 44
Previous stroke 17
IHD 0
CHF 0
Current medications
Antiplatelet 61
Anticoagulants 17
Total score of NIHSS before treatment 13 (7
Laboratory data
Glucose (mg/dL) 149.
Creatinine (mg/dL) 1.2 
Platelet ( 103/mL)* 223.
Actual dose of rtPA (mg per kg of body weight) 0.9 
Data are presented as %, median (interquartile range), or mean  sta
*p < 0.05.
CHF Z congestive heart failure; DBP Z diastolic blood pressure; IHD
Stroke Scale; rtPA Z recombinant tissue-type plasminogen activator;and 14 patients after the implementation of the video-
assisted thrombolytic program. The actual doses of rtPA
that those 32 patients were given were 0.9  0.1 mg/kg of
body weight (the recommended dose is 0.9 mg/kg body
weight7). Twelve patients (38%) had an mRS score  2 on
discharge, whereas 6 patients (19%) had sICH after IV rtPA
per NINDS definitions. The baseline characteristics between
the two groups of patients, except for the platelet count,
were not significantly different (Table 1).
There was marked improvement in the main outcome
(DTN time: 94  24 minutes to 57  14 minutes, p < 0.001)
after this program had been initiated (Table 2). The per-
centage of DTN time  60 minutes improved from 11% to
57% (p Z 0.005; OR: 10.7; 95% CI: 1.7e65.3). The door-to-
CT time significantly decreased by an average of 12 mi-
nutes, but the door-to-laboratory results time did not
significantly change. The AIS% also significantly increased
from 2% to 5% (p Z 0.010; OR: 2.5; 95% CI: 1.1e5.4). The
2hr% marginally significantly increased from 18% to 33%
(p Z 0.080; OR: 2.2; 95% CI: 0.9e5.3). There were no sig-
nificant changes in the percentage of mRS scores  2 on
discharge or sICH per NINDS definitions.Discussion
In a typical large-artery ischemic stroke, every 1-minute
delay of thrombolysis will lead to the death of 1.9 million
neuronal cells,9 and every 10-minute delay of thrombolysis
will decrease one chance of functional independence peric stroke who received intravenous recombinant tissue-type
tation of the video-assisted thrombolytic program.
re (n Z 18) After (n Z 14) p
11 68  12 0.297
57 0.718
14 0.672
 26 159  18 0.519
16 88  16 0.226
79 0.631
36 0.712
21 0.266
21 > 0.99
14 0.184
14 0.184
64 > 0.99
14 > 0.99
) 9 (8) 0.517
0  38 148.0  66 0.930
1.1 1.4  1.6 0.773
0  55 186.0  40 0.045
0.1 0.9  0.2 0.816
ndard deviation.
Z ischemic heart disease; NIHSS Z National Institute of Health
SBP Z systolic blood pressure.
Table 2 Comparative outcomes of important thrombo-
lytic therapy parameters before and after the imple-
mentation of the video-assisted thrombolytic program.
Outcome Before
(n Z 18)
After
(n Z 14)
p
Door-to-needle
time (min)*
93  24 57  14 <0.001
DTN  60 min* 11 57 0.005
Door-to-CT time* 32  12 20  11 <0.001
Door-to-laboratory
results time (min)
60  17 51  13 0.340
Onset-to-needle
time (min)
154  36 136  57 0.286
2hr% 19 33 0.080
AIS%* 2 5 0.010
Modified Rankin
scale  2
at discharge
33 43 0.718
sICH per NINDS 17 21 > 0.99
Data are presented as % or mean  standard deviation.
*p < 0.05.
AIS%Z the percentage of recombinant tissue-type plasminogen
activator thrombolysis in all hospitalized patients with acute
ischemic stroke; CT Z computed tomography; DTN Z door-to-
needle; NINDSZ National Institute of Neurological Diseases and
Stroke; sICH Z symptomatic intracerebral hemorrhage; 2hr
% Z the percentage of recombinant tissue-type plasminogen
activator thrombolysis within 3 hours of onset in all hospitalized
patients with acute ischemic stroke who presented within 2
hours of onset.
932 C.-Y. Hsieh et al.100 patients treated.10 The sooner that rtPA is administered
during the hyperacute stage of AIS, the greater the likeli-
hood that the patient will be functionally independent
after treatment.11 Despite this known time dependence of
rtPA efficacy, fewer than 30% of 25,000 rtPA-treated pa-
tients in the US Get With the Guidelines-Stroke (GTWG-
Stroke) program were treated with rtPA within 60 minutes
after arriving at the hospital.12 From our observation in
clinical practice, it may be difficult to make the patients or
their surrogates understand the complex statistics
regarding the risks and benefits of rtPA in only a few mi-
nutes. Poor understanding of such information about
treatment will lead to a time delay in obtaining informed
consent.
The results of the current study indicated that a
thrombolytic program incorporating a short cartoon video
successfully conveyed this type of important information
about IV rtPA thrombolytic therapy to patients who needed
it. The mean DTN time was 57 minutes and percentage of
DTN time  60 minutes was 57% in 2012. The proportion of
patients who underwent the treatment also increased from
2% to 5%. Because we choose patients eligible for throm-
bolytic therapy using the same guidelines before and after
the initiation of our video-assisted thrombolytic program,
the increase in the overall treatment rate may indicate a
better understanding of the benefits related to thrombo-
lytic therapy within 3 hours of symptom onset. Based on
previous practice experience, we found that obtaining
informed consent was one of the most important steps inthrombolysis. Under the chaotic environment of the
emergency department and narrow window for treatment,
it is very difficult for physicians to adequately communicate
the risk and benefit of rtPA to the patient or family. At one
medical center where the time for a brain CT examination
and neurologist’s evaluation had been minimized, only
approximately 6% of patients with AIS who were admitted
within 3 hours of stroke onset received rtPA.13,14 Failure to
obtain informed consent was the reason 21% of the time
why potentially eligible AIS patients did not receive rtPA.14
In addition to shortening of DTN time, our video-assisted
informed consent also improved treatment rate. The
video we used is now available free of charge on the official
website of the Taiwan Stroke Society. Its content has been
approved by stroke experts in Taiwan and it can be used at
any Taiwan hospital. The use of a video can help physicians
to consistently deliver a clear therapeutic risk communi-
cation to the patient or family within a very short time. The
strategy may be adopted by other hospitals to improve the
quality of thrombolytic therapy.
When determining a patient’s appropriate rtPA dosage,
reliance on an oral statement of body weight from the
patient or the surrogate may not be a good practice.
Although the patient- or surrogate-reported body weight
was not significantly different from the actual body weight
measured using a standard scale in the intensive care unit
later (63  13 kg vs. 64  13 kg, pZ 0.29), the shortcut did
result in small overdoses of the thrombolytic agents
(greater than the recommended dose of 0.9 mg/kg body
weight7) in 25% of our patients. Fortunately, the overdoses
did not increase the risk of sICH per NINDS definition (17%
vs. 21% for overdose or not, respectively, p Z 1.00). How-
ever, a dosage error because of an inaccurate estimation of
body weight reportedly is an independent predictor for a
worse outcome after multivariable adjustments according
to one German study.15 Therefore, a new patient bed has
been equipped with a scale to correctly and efficiently
measure the body weight of stroke patients unable to
stand. Body weight can be determined during any of the
breaks (waiting for CT or laboratory results, or the arrival of
a neurologist).
The posttreatment sICH rates of our patients before and
after implementing the video-assisted therapeutic risk
communication program were both higher than those re-
ported in the literature.16,17 It may be because of our
insufficient experience and thrombolytic volume. The
complications of IV rtPA increased if the thrombolytic vol-
ume of the hospital was less than five treatments per
year.18,19 Besides, 12 of our 32 patients had comorbidity of
chronic kidney disease (CKD), defined as an estimated
glomerular filtration rate < 60 mL/min/1.73 m2. We found
that sICH occurred more frequently in patients with CKD
than those without (42% vs. 5%, p Z 0.02). Our findings
were in accordance with results of two previous meta-an-
alyses20,21 that patients with CKD had higher risks of sICH
after thrombolytic therapy than those without (ORs:
2.79e3.38). Platelet dysfunction and coagulation abnor-
mality associated with CKD may account for the higher risk
for bleeding.21 Although CKD is not a contraindication for
rtPA in the current guideline,6,7 further study is warranted
about the safety of thrombolytic therapy for stroke patients
with CKD in Taiwan.
Video-assisted communication of rtPA risk/benefit 933The current study has several limitations. There were
many factors affecting the timeliness of thrombolysis,
including triage, CT performance, neurological consulta-
tion, laboratory support, rtPA administration, and stroke
team cooperation. Although the shortening of DTN time
from 93 minutes to 57 minutes was greater than the
shortening of time to CT or laboratory results, the small
sample size and retrospective study design prevented us
from directly assessing the effect of video-assisted under-
standing. Prospective studies with larger samples and
control of other factors are needed to test the effective-
ness of a thrombolytic program with video-assisted thera-
peutic risk communication. In addition, the overall
treatment results of patients with AIS after they had been
treated with thrombolytic therapy in this study were less
than satisfactory. Despite the marked decrease of DTN
time, we found no improvement in functional outcome
presented as mRS scores  2 on discharge (33% vs. 43%
before and after the program, respectively, p Z 0.718).
This may be because the small sample size of the current
study (n Z 32) provided insufficient power to detect any
improvement in functional outcome. For example, fewer
than 10% of our patients with AIS arrived at the hospital
within 3 hours of symptom onset and we performed
thrombolytic therapy for AIS only once every 3 months in
2011. Shortening the prehospital delay, both by providing
better patient education and by coordinating with the
emergency medical service, is required to increase the use
of rtPA thrombolytic therapy and improve the outcomes of
patients with AIS.
In conclusion, in a community hospital of Taiwan, a
thrombolytic program with video-assisted therapeutic risk
communication significantly decreased the DTN time and
increased the percentage of rtPA thrombolytic therapy in
patients with AIS. Additional studies are warranted to test
whether such a program would be useful in other settings,
such as medical centers, for improving the functional
outcome of patients with AIS.
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